Advanced search
Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 35, 2011 - Issue 3
Submit an article Journal homepage
253
Views
30
CrossRef citations to date
0
Altmetric
PROCEEDINGS 19th ICOC November 2009, London, UK

Efficacy And Safety Of Administration Of Oral Iron Chelator Deferiprone In Patients With Early Myelodysplastic Syndrome

Jaroslav CermakDepartment of Clinical Hematology, Institute of Hematology and Blood Transfusion, Prague, Czech RepublicCorrespondence[email protected]
,
Anna Jonasova1st Department of Internal Medicine, Faculty Hospital, Prague 2, Czech Republic
,
Jana VondrakovaDepartment of Hematology, Faculty Hospital, Palacky University, Olomouc, Czech Republic
,
Lenka WalterovaDepartment of Hematology, Regional Hospital, Liberec, Czech Republic
,
Ivana HochovaDepartment of Hematology, Faculty Hospital, Prague Motol, Czech Republic
,
Magda Siskova1st Department of Internal Medicine, Faculty Hospital, Prague 2, Czech Republic
&
Radana Neuwirtova1st Department of Internal Medicine, Faculty Hospital, Prague 2, Czech Republic
 show all
Pages 217-227 | Published online: 20 May 2011

Citations (30)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Drorit G Merkel & Arnon Nagler. (2014) Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes. Expert Review of Anticancer Therapy 14:7, pages 817-829.
Read now
Vip Viprakasit, Sarayuth Rodmai & Somdet Srichairatanakool. (2014) Deferiprone for transfusional iron overload and its roles in developing countries. Expert Opinion on Orphan Drugs 2:2, pages 189-200.
Read now
Mhairi Mitchell, Steven D Gore & Amer M Zeidan. (2013) Iron chelation therapy in myelodysplastic syndromes: where do we stand?. Expert Review of Hematology 6:4, pages 397-410.
Read now

Articles from other publishers (27)

Juan Jose Rodriguez-Sevilla, Xavier Calvo & Leonor Arenillas. (2022) Causes and Pathophysiology of Acquired Sideroblastic Anemia. Genes 13:9, pages 1562.
Crossref
Mrinal M. Patnaik & Ayalew Tefferi. (2021) Myelodysplastic syndromes with ring sideroblasts ( MDS‐RS ) and MDS /myeloproliferative neoplasm with RS and thrombocytosis ( MDS/MPN‐RS‐T ) – “ 2021 update on diagnosis, risk‐stratification, and management” . American Journal of Hematology 96:3, pages 379-394.
Crossref
Sarah Weber, Anastasia Parmon, Nina Kurrle, Frank Schnütgen & Hubert Serve. (2021) The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia. Frontiers in Immunology 11.
Crossref
P. Fenaux, D. Haase, V. Santini, G.F. Sanz, U. Platzbecker & U. Mey. (2021) Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆. Annals of Oncology 32:2, pages 142-156.
Crossref
Francesca Vinchi, Saskia Hell & Uwe Platzbecker. (2020) Controversies on the Consequences of Iron Overload and Chelation in MDS. HemaSphere 4:3, pages e357.
Crossref
Mrinal M. Patnaik & Ayalew Tefferi. (2019) Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: “2019 Update on Diagnosis, Risk‐stratification, and Management”. American Journal of Hematology 94:4, pages 475-488.
Crossref
Heather A. Leitch, Rena Buckstein, Nancy Zhu, Thomas J. Nevill, Karen W.L. Yee, Brian Leber, Mary-Margaret Keating, Eve St. Hilaire, Rajat Kumar, Robert Delage, Michelle Geddes, John M. Storring, April Shamy, Mohamed Elemary & Richard A. Wells. (2018) Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS. Leukemia Research 74, pages 21-41.
Crossref
Nour M. Moukalled, Fuad A. El Rassi, Sally N. Temraz & Ali T. Taher. (2018) Iron overload in patients with myelodysplastic syndromes: An updated overview. Cancer 124:20, pages 3979-3989.
Crossref
Emanuele Angelucci, Paolo Cianciulli, Carlo Finelli, Cristina Mecucci, Maria Teresa Voso & Sante Tura. (2017) Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes. Leukemia Research 62, pages 108-115.
Crossref
Amer M. Zeidan, Vinod A. Pullarkat & Rami S. Komrokji. (2017) Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome. Critical Reviews in Oncology/Hematology 117, pages 57-66.
Crossref
Sally B. Killick. (2017) Iron chelation therapy in low risk myelodysplastic syndrome. British Journal of Haematology 177:3, pages 375-387.
Crossref
Mrinal M. Patnaik & Ayalew Tefferi. (2017) Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis ( RARS ‐ T ): 2017 update on diagnosis, risk‐stratification, and management . American Journal of Hematology 92:3, pages 297-310.
Crossref
Mrinal M. Patnaik & Ayalew Tefferi. (2016) Chronic Myelomonocytic Leukemia: Focus on Clinical Practice. Mayo Clinic Proceedings 91:2, pages 259-272.
Crossref
Sally B. Killick, Nick Bown, Jamie Cavenagh, Inderjeet Dokal, Theodora Foukaneli, Anita Hill, Peter Hillmen, Robin Ireland, Austin Kulasekararaj, Ghulam Mufti, John A. Snowden, Sujith Samarasinghe, Anna Wood & Judith C. W. Marsh. (2016) Guidelines for the diagnosis and management of adult aplastic anaemia. British Journal of Haematology 172:2, pages 187-207.
Crossref
Valeria Pinto, Manuela Balocco, Ilaria Ambaglio, Giorgio Derchi, Luca Malcovati & Gian Luca Forni. (2015) Iron overload‐related heart failure in a patient with transfusion‐dependent myelodysplastic syndrome reversed by intensive combined chelation therapy. Clinical Case Reports 3:11, pages 952-954.
Crossref
Mrinal M. Patnaik & Ayalew Tefferi. (2015) Refractory anemia with ring sideroblasts and RARS with thrombocytosis. American Journal of Hematology 90:6, pages 549-559.
Crossref
P. Fenaux, D. Haase, G.F. Sanz, V. Santini & C. Buske. (2014) Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 25, pages iii57-iii69.
Crossref
Niraj ShenoyNishanth VallumsetlaEliezer Rachmilewitz, Amit VermaYelena Ginzburg. (2014) Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood 124:6, pages 873-881.
Crossref
June-Won Cheong, Hyeoung-Joon Kim, Kyoo-Hyung Lee, Sung-Soo Yoon, Jae Hoon Lee, Hee-Sook Park, Ho Young Kim, Hyeok Shim, Chu-Myung Seong, Chul Soo Kim, Jooseop Chung, Myung Soo Hyun, Deog-Yeon Jo, Chul Won Jung, Sang Kyun Sohn, Hwi-Joong Yoon, Byung Soo Kim, Young-Don Joo, Chi-Young Park & Yoo Hong Min. (2014) Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia. Transfusion 54:6, pages 1542-1551.
Crossref
Sally B. Killick, Chris Carter, Dominic Culligan, Christopher Dalley, Emma Das-Gupta, Mark Drummond, Helen Enright, Gail L. Jones, Jonathan Kell, Juliet Mills, Ghulam Mufti, Jane Parker, Kavita Raj, Alexander Sternberg, Paresh Vyas & David Bowen. (2014) Guidelines for the diagnosis and management of adult myelodysplastic syndromes. British Journal of Haematology 164:4, pages 503-525.
Crossref
Vip Viprakasit & Worapant Kriengsoontornkij. 2014. A worldwide yearly survey of new data in adverse drug reactions and interactions. A worldwide yearly survey of new data in adverse drug reactions and interactions 419 433 .
David P. Steensma & Norbert Gattermann. (2013) When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?. Best Practice & Research Clinical Haematology 26:4, pages 431-444.
Crossref
Luca MalcovatiEva Hellström-LindbergDavid BowenLionel AdèsJaroslav CermakConsuelo del CañizoMatteo G. Della Porta, Pierre FenauxNorbert GattermannUlrich GermingJoop H. JansenMoshe MittelmanGhulam MuftiUwe PlatzbeckerGuillermo F. SanzDominik SelleslagMette Skov-HolmReinhard StauderArgiris Symeonidis, Arjan A. van de Loosdrecht, Theo de WitteMario Cazzola. (2013) Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122:17, pages 2943-2964.
Crossref
Pierre Fenaux & Lionel Adès. (2013) How we treat lower-risk myelodysplastic syndromes. Blood 121:21, pages 4280-4286.
Crossref
M. Ruivard. (2013) Les chélateurs du fer : quand et comment les utiliser chez l’adulte ?. La Revue de Médecine Interne 34:1, pages 32-38.
Crossref
Jayshree Shah, Sandra E. Kurtin, Louise Arnold, Petra Lindroos-Kolqvist & Sara Tinsley. (2012) Management of Transfusion-Related Iron Overload in Patients With Myelodysplastic Syndromes. Clinical Journal of Oncology Nursing 16:0, pages 37-46.
Crossref
Ayalew Tefferi. (2011) Iron overload and stem cell transplant—and the beat goes on. American Journal of Hematology 86:10, pages 825-826.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.